Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ: NEO )

14.21 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
NeoGenomics Announces Board of Directors' Transition
Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT.... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance Retirement
Exposures COVID-19 Legal Pension
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021
FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter
Second-Quarter 2021 Results and Highlights: - Consolidated revenue increased 40% to $122 million - Clinical Services revenue increased 37% to $101 million - Pharma Services revenue increased 55% to $20... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance Retirement
Exposures COVID-19 Legal Pension
NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021
FT. MYERS, FL / ACCESSWIRE / July 14, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
- Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics To Participate Virtually In Multiple Upcoming Institutional Investor Conferences
FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics To Participate In The Bank of America 2021 Health Care Conference
FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter
First-Quarter 2021 Results and Highlights: - Consolidated revenue increased 9% to $116 million - Clinical Services revenue increased 4% to $96 million - Pharma Services revenue increased 46% to $19... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021
FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.